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Abstract
Background: Variant Creutzfeldt-Jakob disease (vCJD) originally resulted from the consumption
of foodstuffs contaminated by bovine spongiform encephalopathy (BSE) material, with 163
confirmed cases in the UK to date. Many thousands are likely to have been exposed to dietary
infection and so it is important (for surveillance, epidemic modelling, public health and
understanding pathogenesis) to identify genetic factors that may affect individual susceptibility to
infection. This study looked at a polymorphism in the cathepsin D gene (refSNP ID: rs17571)
previously examined in Alzheimer's disease (AD).
Methods: Blood samples taken from 110 vCJD patients were tested for the C-T base change, and
genotype data were compared with published frequencies for a control population using multiple
logistic regression.
Results: There was a significant excess of the cathepsin D polymorphism TT genotype in the vCJD
cohort compared to controls. The TT genotype was found to have a 9.75 fold increase in risk of
vCJD compared to the CT genotype and a 10.92 fold increase compared to the CC genotype.
Conclusion: This mutation event has been observed to alter the protease activity of the cathepsin
D protein and has been linked to an increase in amyloid beta plaque formation in AD. vCJD
neuropathology is characterised by the presence of amyloid plaques, formed from the prion
protein, and therefore alterations in the amyloid processing activity of cathepsin D may affect the
neuropathogenesis of this disease.
Background
Variant CJD is one of the prion diseases, which affect both
humans and animals. It is an acquired disease associated
with infection with bovine spongiform encephalopathy
(BSE), mainly through the ingestion route [1,2], although
three cases have resulted from human-to-human blood
transfusion. [3-5] It is most prevalent in the UK, where
163 confirmed cases have been reported, but has also
been found in smaller numbers in other countries includ-
ing France (24 cases, see Availability and requirements
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section for URL). It is estimated that over 500,000 BSE
infected cattle entered the human food chain [6] and
therefore a significant number of people may have been
exposed to infection. One explanation for the current low
number of cases is that there may be genetic determinants
or influences on susceptibility to infection. One definite
significant genetic risk factor so far identified is being
homozygous for methionine (MM) at codon 129 of the
prion protein gene (PRNP). An individual can be
homozygous for methionine (MM) or valine (VV) or a
heterozygote (MV), and healthy UK controls show geno-
type frequencies of 42% MM, 47% MV, and 11% VV. [7]
All tested patients with vCJD have been PRNP-129 MM.
Homozygous individuals are also found more frequently
in patients with sporadic CJD [8] and iatrogenic CJD. [9]
Attempts to find other genetic associations have used both
human patient samples and experimental animal models.
Analysis of the prion protein gene promoter region iden-
tified three polymorphisms that were more common in
patients than controls however due to the low numbers of
samples tested there was only a weak statistical associa-
tion. [10] Human leukocyte antigen (HLA) typing in vCJD
patients (n = 50) indicated that there was a reduction in
frequency for the class-II type DQ7 compared to sporadic
CJD patients [11] however this association was not main-
tained on testing a larger sample size. [12] Detailed anal-
ysis of a 35 kb sequence flanking the prion gene locus
identified 56 single nucleotide polymorphisms (SNPs)
and one of these showed strong association with sCJD but
not vCJD or iatrogenic CJD. [13] Mouse models of TSE
transmission can provide candidate regions for analysis in
the homologous regions of the human genome. Three
such studies have been published and each has suggested
regions of the mouse genome that have significant associ-
ation with incubation time changes following challenge
with TSE agents. [14-16] These findings have yet to be
assessed further in the homologous human chromosomal
regions.
For this study we selected a SNP in the gene coding for the
cathepsin D protein (CTSD), that had already been the
subject of extensive publications in the field of Alzhe-
imer's disease (AD) a neurodegenerative disease with
some pathological similarities to CJD. (For meta-analysis
of the association of this SNP with risk of AD see: [17])
Cathepsin D is a ubiquitously expressed lysosomal pro-
tease involved in proteolytic degradation, cell invasion,
and apoptosis. Aberrant expression of the gene can lead to
neurodegeneration in both experimental animal models
and humans. [18] Of relevance to this study cathepsin D
has been shown to exhibit a beta-secretase-like role [19],
and could therefore cleave beta amyloid precursor protein
(APP) and promote the cascade leading to deposition of
extracellular amyloid beta-peptide (Aβ), the senile
plaques found in Alzheimer's disease. Additionally, cathe-
psin D has also been suggested to cleave Aβ peptides and
therefore clear the aggregated protein deposits. [20] Lim-
ited publications regarding cathepsin D and forms of CJD
have focused on detection of the protein by immunohis-
tochemical and morphometrical methods. On one hand
these studies have shown co-localisation with the disease
associated form of the prion protein [21,22]. On the other
hand a significant correlation between tissue pathology
and volume of neuronal cathepsin D immunoreactive lys-
osomes was demonstrated [21] emphasizing the role of
cathepsin D in the pathogenesis of prion disease.
The gene encoding cathepsin D (CTSD, OMIM: 116840)
is situated on the short arm of chromosome 11 (11p15.5)
and consists of nine exons. On exon two there is a SNP at
position 224 corresponding to a C-to-T transition result-
ing in a alanine to valine substitution in the translated
protein (refSNP ID: rs17571, RefSeq: NM_001909, Varia-
tion: g.804C>T). Publications have indicated that this
SNP may: modify the secretion or maturation of the cathe-
psin D profragment [23]; lead to a reduction in cerebros-
pinal fluid (CSF) tau concentration in Alzheimer's disease
[24]; and show a decrease in general intelligence testing
scores in a healthy older population [25]. The association
of this SNP with risk of Alzheimer's disease and the pres-
ence of particular pathological features seems to be linked
with the apolipoprotein E (APOE) genotype, but shows
variability amongst populations tested. [17,26-28] A
United Kingdom based study on this SNP has indicated a
genetic association between the SNP, APOE genotype, and
pathological features of Alzheimer's disease (Aβ deposi-
tion). [29]
This study aimed to test the CTSD rs17571:C>T SNP allele
and genotype frequencies in a cohort of variant CJD
patients. The deposition of aggregated prion protein amy-
loid, characteristically in the form of florid plaques, may
be affected by the modified cathepsin D activity through
the CTSD rs17571:C>T SNP, and as such may affect the
risk of an individual developing vCJD.
Methods
Blood samples for this study were taken from 110 patients
during investigation of their case histories in respect to
diagnosis of variant CJD. Consent was given for research
and the study is covered by approval from the Lothian
Health Board, Lothian Research Ethics Committee (refer-
ence MCO/103/90). Each patient was later confirmed as
vCJD, with a classification of either 'definite' or 'probable'
vCJD by either neuropathological examination of post
mortem tissue [30] or by fulfilment of the WHO-adopted
diagnostic criteria (see Availability and requirements sec-
tion for URL) respectively. The median age at onset of
symptoms was 27 (range 12–62) and the mean durationBMC Medical Genetics 2008, 9:31 http://www.biomedcentral.com/1471-2350/9/31
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of the clinical phase was 15 months (range 6–39). 59% (n
= 65) of the patients were male.
DNA was extracted from whole blood using the Qiagen
Blood Mini Kit. A 317 bp region of exon 2 containing the
CTSD rs17571:C>T SNP was amplified following the pub-
lished protocol. [25] The forward oligo was 5'-GTGACAG-
GCAGGAGTTTGGT-3' and the reverse was 5'-
GGGCTAAGACCTCATACTCACG-3', and the cycling pro-
gram was a standard touchdown method (annealing tem-
perature reducing from 65°C to 60°C over 10 cycles). The
amplicon was digested with restriction endonuclease
MwoI (NEB, UK) and products were run on a 1.5% agar-
ose gel, visualised with ethidium bromide.
Allele frequency comparisons were made to UK control
data published by Davidson et al from 767 mentally nor-
mal people aged >50 years. [29] Hardy-Weinberg equilib-
rium (HWE) was assessed in the control population and
the patients using χ2 statistics. Genotypic and allelic fre-
quencies were compared using multiple logistic regres-
sion. All statistical analyses were performed in SPSS
software (version 13).
Results
Table 1 shows the CTSD rs17571:C>T SNP genotype fre-
quencies from analysis of 110 vCJD patients, together
with the published control data. CTSD rs17571:C>T SNP
genotype frequencies were in HWE in patients (p = 0.097)
and controls (p = 0.16). The mutant allele T is present in
the homozygous state in a very small number of controls
(0.3%, n = 2 of 767 tested) but significantly has been
found in almost ten-times more vCJD patients (2.7%, n =
3 of 110 tested). Clearly the numbers of TT individuals are
rare however statistical analysis (Fisher's exact test) of the
SNP genotypes indicates that the differences found are of
statistical significance. Odds Ratio analysis shows that
compared with CT and CC, the TT genotype increases the
risk of vCJD by 9.75 fold and 10.92 fold respectively. The
95% confidence intervals are wide as a result of the small
numbers of TT individuals.
Statistical analysis was performed to determine whether
variation in the clinical features present in vCJD patients
was associated with the CTSD genotype. Neither the age at
onset nor clinical duration of illness showed an associa-
tion (ANOVA and Kruskal-Wallis tests respectively). The
three vCJD patients that were homozygous TT for the SNP
showed clinical and neuropathological features typical of
vCJD.
Discussion
The identification of genetic risk factors that increase an
individual's chance of developing vCJD would help to
understand why the present number of cases is low,
despite a potentially significant population exposure to
infection, and also assist in the prediction of the number
of future cases. Genetic factors are likely to be those that
affect expression, maturation, or function of a protein and
therefore may provide evidence for cellular processes that
play key roles in vCJD disease pathogenesis (which
remains incompletely understood). The characterisation
of prion protein and amyloid precursor protein gene
mutations show direct links to familial CJD and Alzhe-
imer's respectively, however these diseases like many oth-
ers are likely to be affected by a significant number of
other genomic and proteomic components. Genomic
approaches to studying vCJD have yet to be published and
may be difficult to interpret due to the small number of
cases available for testing, so we are reliant on findings
from experimental animal models and other diseases that
involve neurodegeneration and protein misfolding/aggre-
gation, such as Alzheimer's and Huntington's disease.
Currently the only polymorphic gene sequence that shows
direct association with vCJD is the prion protein gene
codon 129. All patients so far tested (146/163) were
methionine homozygous (MM) a genotype present in
only ~40% of the UK population. The idiopathic form of
CJD (sporadic CJD) similarly shows an over-abundance
of MM in patients (~70%) [8] and therefore this genotype
has a significant risk associated with development of these
human prion diseases. It is proposed that all codon 129
genotypes may be susceptible to vCJD and that the MM
hosts have the shortest incubation time. [31-33] MV and
VV individuals may present with vCJD in second and third
waves of the epidemic at a later date. [34] It is also possi-
ble that these few specific MM individuals have additional
genomic variations that have significant additive effects,
leaving them highly susceptible to developing vCJD.
Table 1: Summary of CTSD rs17571:C>T SNP genotyping and statistical analysis for vCJD patients and UK controls [29].
CTSD rs17571: C>T SNP vCJD n (%) Controls n (%) Fisher's exact test p-value OR (95% CI); p-value
CC 89 (80.9) 648 (84.5) 0.023 OR TT/CC = 10.92 (1.80–66.26); 0.009
CT 18 (16.4) 117 (15.3) OR TT/CT = 9.75 (1.52–62.47); 0.016
TT 3 (2.7) 2 (0.3)
C 196 (89.1) 1413 (92.1) 0.13 OR T/C = 1.43 (0.90–2.27); 0.11
T 24 (10.9) 121 (7.9)BMC Medical Genetics 2008, 9:31 http://www.biomedcentral.com/1471-2350/9/31
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This study aimed to assess the influence of a missense pol-
ymorphism (C-T; Alanine – Valine) at position 224 of the
cathepsin D protein on risk of vCJD. This polymorphism
has been extensively investigated with respect to Alzhe-
imer's disease (AD). A meta-analysis from 2004 [17] cov-
ering 14 studies concluded that CTSD rs17571:C>T was
not a major risk factor for AD, however in conjunction
with the APOE4 genotype it had an effect on susceptibil-
ity. There was significant between-study heterogeneity
possibly due to comparing data from many countries with
variable  CTSD  rs17571:C>T genotype frequencies. The
vCJD samples available for this study were from Cauca-
sian patients resident in the UK. The control group were
also Caucasian individuals from the UK. It is therefore
believed that geographical origin of patients and controls
would not affect the analysis.
A recent UK study, from which we have taken the control
population frequencies, found a correlation between
CTSD rs17571:C>T and the pathogenesis of AD. [29] Spe-
cifically there was an increase in the number of senile
plaques containing Aβ40 in the brain associated with the T
allelic variant of cathepsin D. This variant is thought to
have a greater beta-secretase activity than the C variant
therefore yielding more of the cleaved Aβ which in turn
may accelerate AD pathogenesis by seeding amyloid for-
mation [23,29,35]. Risk of developing AD was not found
to be directly affected by the possession of the CTSD
rs17571:C>T T allele.
There remains a possibility that the CTSD rs17571:C>T
SNP is in linkage disequilibrium with another neighbour-
ing gene on chromosome 11 that may be the direct cause
of the findings in this study. CTSD is located in a region
of chromosome 11 (11p15.5) that contains genes for a
number of transmembrane proteins and cell surface glyc-
oproteins, such as CD81, SYT8, TSPAN4, TSPAN32, that
may have roles in common with prion protein. Also
present is DUSP8, a phosphatase inhibitor of members of
the mitogen-activated protein kinase (MAPK) superfamily
that are associated with cell differentiation, proliferation,
and apoptosis in the adult brain.
Conclusion
The study detailed here found an over-representation of
the CTSD rs17571:C>T T allele in UK vCJD patients sug-
gesting an increase in risk of developing the disease. We
hypothesize that concurrent with the beta-secretase activ-
ity, cathepsin D may also have amyloidogenic properties
through either promoting the formation or reducing the
clearance of amyloid. Deposition of PrP amyloid is a char-
acteristic neuropathological finding in vCJD that is only
rarely seen in some molecular subtypes of the more com-
mon diagnosed forms of sporadic CJD. Continuing stud-
ies of vCJD patients must therefore examine PrP amyloid
plaque biochemistry and histology to observe the effect of
the cathepsin T allele. This may open new avenues of
research to allow for a better understanding of the patho-
genesis of vCJD.
Identifying genetic factors that increase an individual's
risk of developing vCJD may also be beneficial for assess-
ing the relative risk of human-to-human transmission of
vCJD, as has been observed via blood transfusion. [3-
5,36]
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